seroepidemiolog
studi
conduct
north
china
determin
neutral
antibodi
titer
sever
acut
respiratori
syndrom
sar
convalesc
sera
total
sar
convalesc
serum
sampl
collect
patient
inner
mongolia
autonom
region
hebei
provinc
beij
day
onset
symptom
antisar
antibodi
detect
enzymelink
immunosorb
assay
elisa
neutral
assay
western
blot
eightyseven
serum
sampl
confirm
posit
sar
antibodi
neutral
antibodi
titer
posit
sera
analyz
quantit
neutral
assay
geometr
mean
titer
gmt
convalesc
sera
kolmogorovsmirnov
test
show
neutral
antibodi
titer
conform
normal
distribut
suggest
averag
antisar
antibodi
level
studi
repres
convalesc
antibodi
level
sar
popul
result
could
use
develop
qualiti
control
sar
vaccin
sever
acut
respiratori
syndrom
sar
newli
emerg
sever
acut
respiratori
syndrom
caus
sar
coronaviru
sarscov
import
public
health
kuiken
et
al
juli
case
sar
report
infect
patient
die
april
may
china
report
nine
new
laboratoryacquir
sar
case
prevent
futur
recurr
sar
dozen
sar
candid
vaccin
develop
gao
et
al
bisht
et
al
marshal
enserink
yang
et
al
urgent
need
accur
measur
sar
convalesc
serum
antibodi
level
refer
evalu
efficaci
vaccin
mani
effort
devot
quantifi
sarscov
specif
antibodi
titer
use
enzymelink
immunosorb
assay
elisa
shi
et
al
huang
et
al
result
compar
among
differ
studi
one
report
igg
antibodi
titer
convalesc
serum
measur
indirect
elisa
around
anoth
report
antibodi
measur
specif
recombin
sar
nucleocapsid
n
protein
titer
express
logarithm
liu
et
al
sinc
standard
reagent
sar
antibodi
detect
becom
avail
data
sar
antibodi
titer
report
variou
research
applic
sar
vaccin
evalu
neutral
assay
measur
abil
sera
neutral
infect
sarscov
cell
cultur
stabl
method
involv
extern
reagent
gain
comprehens
understand
antibodi
sarscov
report
antisar
antibodi
titer
sar
convalesc
sera
determin
neutral
assay
provid
import
inform
develop
sar
vaccin
ninetynin
serum
sampl
convalesc
sar
patient
collect
day
onset
symptom
may
septemb
seventyf
collect
inner
mongolia
autonom
region
hebei
provinc
beij
sar
patient
confirm
sar
case
accord
diagnosi
criteria
promulg
ministri
health
pr
china
medic
histori
close
contact
sar
patient
symptom
fever
higher
cough
difficulti
breath
reticular
chang
flaki
stripe
infiltr
shadow
chest
xray
examin
white
blood
cell
wbc
count
rise
effect
treatment
antibiot
panel
serum
sampl
obtain
healthi
adult
neg
control
serum
sampl
steril
mm
filter
heatinactiv
min
sarscov
sino
strain
isol
pharyng
swab
clinic
confirm
sar
patient
peke
union
hospit
sino
strain
wellcharacter
biolog
confirm
electron
microscop
observ
complet
genom
sequenc
genbank
access
vero
cell
line
african
green
monkey
kidney
cell
obtain
atcc
american
type
cultur
collect
vero
cell
grown
minimum
essenti
medium
mem
contain
wv
newborn
calf
serum
wv
glutamin
sarscov
propag
vero
cell
cultur
flask
cell
show
cytopath
effect
cpe
three
freezethaw
cycl
viru
harvest
character
neutral
assay
batch
sarscov
inactiv
bpropiolacton
situ
flask
purifi
centrifug
ultrafiltr
gel
filtrat
purifi
sarscov
use
antigen
western
blot
assay
vero
cell
cultiv
plate
form
confluent
monolay
cell
inocul
ml
per
well
viral
suspens
dilut
serial
tenfold
step
mem
contain
newborn
calf
serum
mgml
penicillin
ph
dilut
fill
well
plate
incub
co
incub
viru
titer
express
cell
cultur
infecti
dose
ccid
dilut
viru
caus
half
cultur
cell
produc
cpe
viru
batch
titer
lg
ccid
ml
store
neutral
assay
purifi
sarscov
sino
strain
protein
separ
sdspage
transfer
onto
nitrocellulos
membran
block
membran
incub
test
serum
sampl
dilut
primari
antibodi
secondari
antibodi
goat
antihuman
igg
conjug
hrp
color
develop
substrat
dab
recombin
n
protein
includ
test
posit
antigen
n
protein
brand
purifi
sarscov
show
molecular
weight
kda
detect
serum
use
consid
sar
antibodi
posit
elisa
perform
use
commerci
sar
coronaviru
igg
antibodi
diagnost
kit
bgigbi
biotech
co
ltd
beij
china
accord
manufactur
instruct
test
sera
dilut
ten
time
ad
elisa
strip
well
coat
sarscov
lysat
process
wash
ad
hrplabel
antihuman
igg
color
develop
stop
reaction
absorb
optic
densiti
nm
od
measur
neutral
assay
conduct
accord
convent
procedur
briefli
ml
dilut
serum
twofold
serial
dilut
ad
equal
volum
viru
dilut
ccid
ml
incub
hr
mixtur
ad
confluent
monolay
vero
cell
plate
incub
co
incub
day
day
presenc
viral
cpe
check
dilut
serum
complet
inhibit
cpe
cell
calcul
use
reedmuench
formula
reed
muench
posit
neg
control
includ
test
meanwhil
assay
sarscov
retitr
infect
ccid
ml
parallel
neutral
assay
experi
system
valid
first
welltitr
sar
inhous
refer
antiserum
geometr
mean
titer
gmt
use
posit
control
zhang
et
al
test
result
show
neutral
antibodi
titer
neg
control
sera
therefor
neutral
antibodi
titer
equal
higher
defin
posit
neutral
assay
taken
valid
titer
posit
control
rang
titer
neg
serum
experi
repeat
three
time
three
person
simultan
ninetynin
serum
sampl
dilut
firstli
qualit
test
neutral
assay
posit
sera
serial
dilut
quantit
test
neutral
antibodi
titer
normal
distribut
analysi
perform
one
sampl
kolmogorovsmirnov
test
use
spss
softwar
level
signific
set
p
total
sar
convalesc
sera
includ
research
sampl
test
qualit
antibodi
respons
sarscov
elisa
neutral
assay
parallel
sampl
test
western
blot
sampl
elisa
detect
posit
sera
neutral
assay
identifi
posit
sera
eightysix
sera
posit
elisa
neutral
assay
tabl
neutral
assay
detect
one
posit
serum
result
obtain
elisa
neutral
assay
serum
sampl
confirm
posit
evid
western
blot
though
neg
elisa
neutral
posit
sampl
test
western
blot
posit
antisar
antibodi
tabl
serum
sampl
confirm
posit
antisar
antibodi
combin
elisa
neutral
western
blot
pool
form
convalesc
sera
databas
analysi
neutral
antibodi
titer
remain
serum
sampl
rule
neg
evid
neutral
assay
western
blot
elisa
antisar
neutral
antibodi
titer
posit
convalesc
sera
analyz
quantit
neutral
assay
titer
collect
day
onset
symptom
test
neutral
assay
result
shown
figur
lowest
titer
detect
neutral
assay
highest
titer
gmt
convalesc
sera
test
result
show
sar
specif
neutral
antibodi
level
rel
stabl
persist
long
day
slight
declin
day
onset
symptom
tabl
ii
normal
distribut
test
antisar
titer
perform
one
sampl
kolmogorovsmirnov
test
use
spss
softwar
log
transform
titer
test
result
show
pvalu
p
reveal
antisar
neutral
antibodi
titer
normal
distribut
conclus
drawn
averag
antisar
neutral
antibodi
level
convalesc
sera
obtain
studi
repres
convalesc
neutral
antibodi
level
sar
popul
outbreak
sar
elisa
immunofluoresc
assay
western
blot
neutral
assay
use
serolog
diagnosi
sar
case
elisa
wide
use
assay
possess
sensit
specif
report
wu
et
al
object
investig
provid
profil
antisar
neutral
antibodi
sera
doubl
posit
elisa
neutral
assay
remain
serum
doubl
posit
neutral
assay
western
blot
titer
convalesc
patient
rather
establish
neutral
assay
diagnost
method
sar
laboratori
combin
elisa
neutral
assay
western
blot
perform
sar
convalesc
sera
use
method
sera
confirm
posit
antisar
antibodi
result
neutral
assay
accord
elisa
western
blot
high
level
consist
demonstr
elisa
neutral
assay
posit
sampl
illustr
high
sensit
specif
neutral
assay
gmt
antisar
neutral
antibodi
quantit
normal
distribut
neutral
antibodi
titer
shown
statist
analysi
neutral
assay
could
therefor
becom
use
tool
surveil
sar
serolog
epidemiolog
demonstr
mous
model
neutral
antibodi
elicit
primari
infect
sarscov
protect
anim
reinfect
addit
passiv
transfer
immun
serum
mice
prevent
sarscov
replic
respiratori
tract
yang
et
al
show
dna
vaccin
encod
spike
glycoprotein
sarscov
induc
mice
gener
tcell
neutral
antibodi
respons
well
protect
immun
respons
demonstr
protect
mediat
humor
tcelldepend
immun
mechan
tcell
deplet
passiv
transfer
purifi
igg
although
investig
humor
cellular
immun
need
human
reason
conclud
human
neutral
antibodi
protect
sarcov
develop
sar
vaccin
entail
method
best
reflect
immun
respons
human
evalu
vaccin
efficaci
neutral
assay
satisfi
requir
specif
correl
humor
immun
respons
sar
convalesc
patient
addit
unlik
serolog
test
base
subunit
n
protein
neutral
assay
detect
effect
neutral
antibodi
specif
character
uncharacter
epitop
although
neutral
assay
gold
standard
sever
disadvantag
limit
wide
use
cumbersom
expens
need
biosafeti
contain
risk
infect
manipul
sarscov
might
bring
risk
research
also
public
sar
laboratori
infect
case
report
taiwan
singapor
chines
mainland
watt
averag
neutral
antibodi
titer
sarscov
convalesc
serum
undoubtedli
one
import
index
refer
sar
candid
vaccin
assess
